Recent studies on retatruded, a dual agonist for incretin hormone and GIP, demonstrate encouraging results in managing obesity and type 2 glucose intolerance. Preliminary evidence from clinical experiments point to substantial decreases in body bulk and improved glucose regulation. Ongoing exploration is directed on long-term harmlessness and ef… Read More